NADPH oxidase gene therapy - Genethon

Drug Profile

NADPH oxidase gene therapy - Genethon

Alternative Names: Chronic granulomatous disease gene therapy - Genethon; g1xcgd; G1XCGD transduced CD34+ cells; Lentiviral vector transduced CD34+ cells

Latest Information Update: 27 Aug 2015

Price : $50

At a glance

  • Originator Genethon
  • Developer Genethon; University of California at Los Angeles
  • Class Gene therapies
  • Mechanism of Action Gene transference; NADPH oxidase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Chronic granulomatous disease
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Chronic granulomatous disease

Most Recent Events

  • 29 Jul 2015 Phase-I/II clinical trials in Chronic granulomatous disease (In children, In adolescents, In adults) in USA (IV) (NCT02234934)
  • 04 Sep 2014 The University of California at Los Angeles and Genethon plan a phase I/II trial for Chronic granulomatous disease in USA (NCT02234934)
  • 14 May 2013 Genethon completes enrolment in its phase I/II trial for Chronic granulomatous disease in United Kingdom, France, Germany & Switzerland (NCT01855685)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top